Group 1 - Wanhua Chemical's Yantai Industrial Park's ethylene unit has completed a technical upgrade and resumed production, achieving flexible feedstock switching between ethane and propane, enhancing competitiveness in the petrochemical industry [1] - United Water has won a long-term operation contract for municipal wastewater treatment in Saudi Arabia, with an estimated total investment of approximately 378 million RMB over a 15-year cooperation period [2] - Minsheng Health plans to invest 98 million RMB to establish a fund focused on the health industry, contributing 49% of the total fund size of 200 million RMB [3] Group 2 - Jialitu's shareholder, Anle Group, plans to reduce its stake by up to 3% of the company's total shares [4] - Laiyifen's controlling shareholder intends to reduce its stake by no more than 3% of the total shares [5] - Taifu Pump's actual controller's concerted action party plans to reduce its stake by up to 0.535% [7] Group 3 - Vanke A's executive vice president, Yu Liang, has resigned due to retirement [8] - Tian Sheng New Materials has suspended trading due to a potential change in control involving its largest shareholder [10] - Taisun Wind Power is in the early stages of business layout in the commercial aerospace sector [11] Group 4 - Lushin Investment holds only 0.89% equity in Blue Arrow Aerospace, indicating minimal impact on its financial status [12] - Huibo Pu's controlling shareholder is planning a change in control, leading to stock suspension [13] - Tubaobao's subsidiary is selling a stake in Daziran Home and acquiring specific equity for 4 billion RMB [14] Group 5 - Xingchen Technology plans to repurchase shares worth between 60 million and 120 million RMB for employee stock ownership plans [15] - Pulite expects no large-scale orders for its LCP film products in the brain-computer interface sector in the short term [16] - Rijiu Optoelectronics plans to raise up to 800 million RMB through a private placement for a functional film project [17] Group 6 - Yingqu Technology forecasts a net profit increase of 114.69% to 162.4% in 2025, with expected revenue growth of 13% to 18% [19] - Shanda Electric has won a project from Southern Power Grid worth approximately 13.43 million RMB [20] - Changhong Technology's subsidiary has secured over half of a major semiconductor customer's procurement share, amounting to over 10 million RMB [21] Group 7 - Pairui Co. has signed a framework agreement for bulk procurement of IGBT chips, with projected orders totaling approximately 1.74 billion RMB [22] - Aimeike has received a drug registration certificate for its exclusive distribution of injectable botulinum toxin products in China [23] - Quanyin High-Tech's stock will resume trading after a takeover offer from Zhongzhong Group, which now holds 40.51% of the company [24] Group 8 - Hailiang Co. has decided to suspend its investment in Jinlong Group due to significant external changes [25] - Quanxin Co. plans to issue convertible bonds to raise up to 312 million RMB for aviation communication projects [26] - Kangtai Bio's clinical trial application for a combined vaccine has been accepted by the National Medical Products Administration [27] Group 9 - Huaxia Happiness expects to report a net loss for 2025, with losses projected to exceed the previous year's audited net assets [28] - Xianju Pharmaceutical has received a drug registration certificate for Betamethasone Sodium Phosphate Injection [29] - Huaxia Happiness's controlling shareholder is involved in arbitration with a claim amount of approximately 6.4 billion RMB [30] Group 10 - Shaoneng Co. has launched its smart control center project, with an investment of 8.7 million RMB [31] - Jiangshun Technology is planning to establish an investment fund with professional institutions, with details still under discussion [32] - Beifang Changlong intends to acquire 51% of Shunyi Technology, which may constitute a major asset restructuring [33] Group 11 - Guoji Heavy Industry's revenue from "controlled nuclear fusion" products is currently negligible [34] - Hongrun Construction's shareholder plans to reduce its stake by up to 0.12% [35] - Puni Testing expects a net loss of 200 to 250 million RMB for 2025, although this represents an improvement from the previous year's loss [36] Group 12 - Kede Education's controlling shareholder is planning a change in control through a share transfer agreement [38] - Zhongwei Company’s major shareholder plans to reduce its stake by up to 2% [39] - Tongcheng New Materials is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [40] Group 13 - ST Jianyi's shareholder plans to reduce its stake by up to 1.23% [41]

（编辑 丛可心） 证券日报网讯 1月8日，仙琚制药发布公告称，公司近日获国家药监局核准签发倍他米松磷酸钠注射液 《药品注册证书》，规格1ml：4mg（按C₂₂H₂₉FO₅计），属化学药品3类，用于需糖皮质激素治疗疾 病，已视同通过一致性评价，将丰富产品线。 ...

智通财经APP讯，仙琚制药(002332.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于倍他米 松磷酸钠注射液的《药品注册证书》，公司倍他米松磷酸钠注射液被批准注册。倍他米松磷酸钠注射液 主要用于需要使用糖皮质激素治疗的疾病。 ...

格隆汇1月8日丨仙琚制药(002332.SZ)公布，近日收到国家药品监督管理局核准签发的关于倍他米松磷 酸钠注射液的《药品注册证书》（证书编号：2026S00006），公司倍他米松磷酸钠注射液被批准注 册。倍他米松磷酸钠注射液，规格1ml：4mg（按C₂₂H₂₉FO₅计），参比制剂为欧盟上市的倍他米松磷酸 钠注射液，商品名Celestone®。倍他米松磷酸钠注射液最早由先灵葆雅公司开发,持证商最终变更为 Organon公司。倍他米松磷酸钠注射液主要用于需要使用糖皮质激素治疗的疾病。Organon公司的倍他米 松磷酸钠注射液已在比利时、瑞典、荷兰、德国、法国、波兰等多个国家上市。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Betamethasone Sodium Phosphate Injection, which is expected to enhance its product line and competitiveness [1] Group 1: Product Approval - The approved drug is Betamethasone Sodium Phosphate Injection, with a specification of 1ml: 4mg (calculated as C₂₂H₂₉FO₅) [1] - The registration classification of the drug is categorized as Class 3 chemical drugs [1] Group 2: Market Impact - The drug is primarily used for the treatment of diseases related to glucocorticoids, and the original drug has been marketed in multiple countries [1] - The approval is seen as beneficial for the company in terms of expanding its product offerings and improving its competitive position in the market [1] Group 3: Uncertainties - The research, production, and sales of the drug are subject to uncertainties influenced by policies and market factors [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局核准签发的关于倍他米松磷酸钠注射液的《药品注册证书》（证书编号： 2026S00006），公司倍他米松磷酸钠注射液被批准注册。现将相关情况公告如下： 申请内容：境内生产药品注册上市许可。 证券代码：002332 证券简称：仙琚制药 公告编号：2026-001 浙江仙琚制药股份有限公司 关于取得倍他米松磷酸钠注射液境内生产药品注册证书的公告 由于药品研发、生产和销售容易受到国家政策、市场环境等因素影响，具有 较大不确定性，敬请广大投资者注意投资风险。 特此公告。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他相关情况 倍他米松磷酸钠注射液，规格1ml：4mg（按C₂₂H₂₉FO₅计），参比制剂为欧盟 上市的倍他米松磷酸钠注射液，商品名Celestone®。倍他米松磷酸钠注射液最早 由先灵葆雅公司开发,持证商最终变更为Organon公司。倍他米松磷酸钠注射 ...

Core Viewpoint - The fourth batch of encouraged generic drug catalog was released, including 21 drug varieties and 47 specifications, addressing the issue of drug shortages in China and aiming to enhance domestic drug development and production capabilities [1][2]. Group 1: Drug Catalog Expansion - The fourth batch of the catalog is an update after two years, bringing the total number of encouraged generic drug varieties to 110, following three previous batches released in 2019, 2021, and 2023, which included 89 drugs [1]. - The new catalog continues to focus on major diseases such as cancer and rare diseases, while also addressing shortages in treatments for chronic diseases, mental health, and assisted reproduction, reflecting the changing disease burden and clinical needs due to demographic trends [1][2]. Group 2: Selection Criteria and Focus Areas - The selection of drugs for the fourth batch was guided by patient treatment needs, considering clinical guidelines and domestic research status, with input from experts across various fields [2]. - New entries include drugs targeting new mechanisms and indications, such as a treatment for severe itching in chronic kidney disease patients undergoing dialysis and four radioactive drugs not yet marketed domestically [2]. Group 3: Specific Drug Examples - The inclusion of Suvorexant, a drug for insomnia, aims to address the high prevalence of insomnia symptoms among the Chinese population, with 59% of surveyed residents reporting such issues [3]. - The catalog also includes a vaginal sustained-release gel of progesterone for assisted reproduction, which aims to alleviate adverse reactions from traditional injection methods, although it faces regulatory challenges in the domestic market [4]. Group 4: Challenges in Generic Drug Development - Despite being a major player in generic drugs, China faces challenges in becoming a "strong country" in this sector, including technical barriers and insufficient incentives for research and development [5]. - As of September last year, only 40 out of 89 drugs from the previous three catalogs had been approved for market, indicating that many drugs remain unavailable for domestic generic production [5]. Group 5: Future Support and Policy Directions - The government aims to enhance the enthusiasm for generic drug development through policies that provide market exclusivity for certain categories of drugs, including those for rare diseases and children's medications [6]. - Future efforts will focus on supporting clinical trials, key technology research, and expedited review processes for drugs listed in the encouraged generic drug catalog [6].

Core Viewpoint - The fourth batch of encouraged generic drug catalog has been released, including 21 drug varieties and 47 specifications, addressing the shortage of clinical supplies and the need for domestic drug development [1][2]. Group 1: Drug Catalog Expansion - The fourth batch of the encouraged generic drug catalog includes 21 drug varieties, bringing the total to 110 since the first three batches were released in 2019, 2021, and 2023 [1]. - The new catalog focuses on major diseases such as cancer and rare diseases, as well as chronic diseases, mental health issues, and reproductive health, reflecting the changing disease burden and clinical needs due to demographic trends [1][2]. Group 2: Selection Criteria and Clinical Needs - The selection of drugs for the fourth batch was guided by patient treatment needs, considering clinical guidelines and domestic research status, with input from various experts [2]. - New drugs with novel targets and mechanisms, such as those for chronic kidney disease-related itching, have been included, along with radioactive drugs not yet available in the domestic market [2]. Group 3: Specific Drug Examples - Suvorexant, a new drug for insomnia, has been included in the catalog to address the high prevalence of insomnia symptoms among the Chinese population, with 59% of surveyed residents reporting such issues [3]. - The catalog also includes drugs for rare diseases, such as Deflazacort for Duchenne muscular dystrophy, and aims to enhance reproductive health with low-adverse-effect products [3][4]. Group 4: Challenges in Generic Drug Development - Despite being a major player in generic drugs, China faces challenges in becoming a stronghold in this sector due to technical barriers and insufficient incentives for research and development [5][6]. - As of September last year, only 40 out of 89 drugs listed in the previous three catalogs had been approved for market entry, indicating a significant gap in the availability of generic drugs [5]. Group 5: Future Support and Policy Directions - The government aims to enhance support for the encouraged generic drug catalog through improved clinical trials, key technology research, and expedited review processes [6]. - Policies are being developed to provide market exclusivity for certain categories of drugs, including those for rare diseases and children's medications, to stimulate research and development [6].

Core Insights - The article discusses the competitive landscape of the hair medical industry in China, highlighting key players and market dynamics [1][5]. Group 1: Competitive Landscape - The Chinese hair medical industry features various competitive factions, with companies like Yonghe Medical, Damaik, and Qingyi focusing on hair transplant medical services, while SanSheng Pharmaceutical, Zhendong Pharmaceutical, and Xianju Pharmaceutical are involved in medical nurturing services [1]. - In the hair transplant sector, the first tier consists of leading national chain brands such as Yonghe Medical, Bilian Sheng, and Damaik, which collectively hold a significant market share and possess nationwide direct chain layouts, mature technology systems, and strong brand recognition [1]. Group 2: Hair Growth Pharmaceuticals - In the hair growth pharmaceuticals market, the first tier includes SanSheng Pharmaceutical, Zhendong Pharmaceutical, and Merck, with the former two holding major shares in the minoxidil market, while Merck is recognized as the original manufacturer of finasteride [5]. - The second tier comprises Xianju Pharmaceutical, Kang En Bei, and Xiamen Meishang Pharmaceutical, which have accelerated the launch of minoxidil and finasteride products in recent years, gaining notable market recognition [5]. Group 3: Sales Performance - In the online pharmacy sector, Zhejiang SanSheng's minoxidil tincture product achieved sales exceeding 1 billion yuan, while Zhendong Anxin's minoxidil lotion surpassed 300 million yuan in sales, and SanSheng's minoxidil foam also exceeded 100 million yuan [9]. - In the offline market during the first quarter of 2025, Zhejiang SanSheng's minoxidil tincture and Zhendong Anxin's minoxidil lotion both recorded sales above 20 million yuan, with market shares of 50.61% and 38.82%, respectively [10]. - The sales ranking for minoxidil products shows Zhejiang SanSheng's minoxidil tincture leading with over 34 million yuan in sales (50.61% market share), followed by Zhendong Anxin's minoxidil lotion with over 26 million yuan (38.82% market share) [11].

证券日报网讯12月26日，仙琚制药（002332）在互动平台回答投资者提问时表示，股价波动受宏观经 济、行业环境、市场情绪、公司发展阶段等多种因素影响。 ...